<DOC>
	<DOCNO>NCT00168727</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness treatment regimen use Zevalin® plus Rituxan® patient low grade Non-Hodgkin ’ Lymphoma ( NHL ) relapse Non-Hodgkin ’ lymphoma previously treat . This study use experimental schedule regimen . No chemotherapy use study .</brief_summary>
	<brief_title>Zevalin® Followed Rituxan® Maintenance Previously Treated Low Grade Non-Hodgkin ’ Lymphoma</brief_title>
	<detailed_description>The objective study determine overall response rate , event-free survival , time-to-progression , time-to-next-therapy , freedom-from-relapse patient low-grade lymphoma first second relapse treat Zevalin follow 2 year Rituxan maintenance therapy multicenter , community-based setting , well evaluate relative response rate population without prior rituximab therapy , first versus second relapse , without bulky ( &gt; 5 cm great diameter ) disease . To meet initial trial enrollment goal 300 patient two year , 42 total site activate . The study subsequently close accrual . Currently 8 site remain active follow 12 subject enrol past year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Follicular nonHodgkin ’ lymphoma include SLL first second relapse . No anticancer therapy three wks ( six wks nitrosourea Mitomycin C ) ; rituximab refractory . Age &gt; = 18 year , pregnant lactating . Expected survival &gt; = 3 mths ; PS 0 , 1 , 2 . ANC &gt; = 1,500/mm3 , platelet count &gt; = 100,000/mm3 . Total bilirubin &gt; 2.0 mg/dL , creatinine &gt; 2.0 mg/dL . Total lymphocyte count &lt; 5,000/mm3 SLL . &lt; 25 % bone marrow involvement lymphoma . Prior ABMT ASCT , hypocellular mark reduction bone marrow precursor , history fail stem cell collection . Bulky area disease 10 cm diameter . Patients CLL , CNS , mantle cell lymphoma . Hx HIV/AIDS relate lymphoma , hepatitis B C. Prior radioimmunotherapy XRT &gt; 25 % active bone marrow . GCSF GMCSF within 2 wks , pegylated GCSF within 4 wks treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Antigens , CD20</keyword>
</DOC>